Document Detail


Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction.
MedLine Citation:
PMID:  7712677     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the efficacy and safety of a 40-hour lidocaine infusion after completion of a 8-hour open-label infusion for prophylaxis of primary ventricular fibrillation in patients with uncomplicated acute myocardial infarction. METHODS: This was a double-blind, randomized placebo-controlled trial held in the coronary care unit of a large nonprofit hospital. We studied 200 patients with uncomplicated acute myocardial infarction in Killip class I or II who came to the hospital within 6 hours of onset of symptoms and 22 patients who had ventricular fibrillation before the start of the study. Intervention consisted of an 8-hour lidocaine infusion followed by placebo or lidocaine for an additional 40 hours. The infusion rate was adjusted in patients > or = 70 years old and in those < 50 kg or > or = 90 kg. Measurements recorded were baseline demographic characteristics, incidence of ventricular arrhythmias, adverse reactions, and death. RESULTS: New congestive heart failure developed during the randomized phase in 9% of patients receiving lidocaine and in 2% of patients receiving placebo (p = 0.03). Ventricular fibrillation did not occur during the treatment period, and sustained ventricular tachycardia developed in one patient receiving placebo. The in-hospital mortality rate was comparable in both groups (4% versus 2%; p = 0.68) but was much higher (13.6%) in patients with initial ventricular fibrillation not included in the randomized study. CONCLUSIONS: A 40-hour age- and weight-adjusted lidocaine infusion administered after an initial 8-hour infusion provoked more congestive heart failure than placebo. In view of the absence of ventricular fibrillation episodes with both infusions, caution should be used when lidocaine is administered for longer than 8 hours in patients with uncomplicated myocardial infarction.
Authors:
C Pharand; J Kluger; E O'Rangers; M Ujhelyi; J Fisher; M Chow
Related Documents :
2632837 - Effects of propranolol on coronary vasculature and cardiac performance in dogs with fix...
2968237 - Thyroxine-induced cardiac hypertrophy: time course of development and inhibition by pro...
954817 - The positive inotropic and chronotropic actions of some amino acids and their effects i...
94407 - Increased diastolic time: a possible important factor in the benefical effect of propra...
10323517 - Critical obstruction of the right ventricular outflow tract by a primary hemangioendoth...
7496617 - Advances in atherosclerosis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  57     ISSN:  0009-9236     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  1995 Apr 
Date Detail:
Created Date:  1995-05-16     Completed Date:  1995-05-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  471-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Pharmacy Services, Hartford Hospital, CT 06115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Double-Blind Method
Female
Heart Failure / chemically induced
Hospital Mortality
Humans
Infusions, Intravenous
Lidocaine / administration & dosage,  adverse effects,  therapeutic use*
Male
Myocardial Infarction / complications*,  mortality
Time Factors
Treatment Outcome
Ventricular Fibrillation / etiology,  mortality,  prevention & control*
Chemical
Reg. No./Substance:
137-58-6/Lidocaine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine i...
Next Document:  Streptozotocin and alloxan are comparable agents in the diabetic model of impaired wound healing.